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1. Introduction  
1.1 Role of lipoproteins 
Lipoproteins provide the means of transport of hydrophobic lipids in the circulation (Havel 
& Kane, 1995). Composed of a single monolayer of phospholipids surrounding a neutral 
lipid core, the primary purpose of these spherical lipid particles is to deliver two major 
classes of lipids – cholesterol and fatty acids (FA) - to the different peripheral tissues. 
Cholesterol is carried in the form of free unesterified form in the phospholipid monolayer, 
or as cholesteryl esters (CE) in the nucleus of the lipoprotein. FA are transported in the form 
of triglycerides (TGs), also found in the hydrophobic core of the lipid particles along with 
the CE. Proteins that are amphipathic in nature are found associated with the lipoprotein 
and are referred to as apolipoproteins (apo). They serve as cofactors for lipid-modifying 
enzymes and proteins, including lipoprotein lipase, hepatic lipase, lecithin-cholesterol 
acyltransferase and cholesteryl-ester transfer protein. Apolipoproteins also serve as ligands 
that bind to specific sites of lipoprotein receptors, providing a means by which the 
lipoproteins are bound and then internalized through endocytosis via these receptors 
located on cell surface membranes.  
1.2 Triglyceride-rich lipoproteins  
TGs transported by lipoproteins can be either of endogenous or exogenous origin (Figure 1). 
Upon absorption through the intestinal wall, dietary TGs are repackaged by the enterocyte 
into very large TG-rich chylomicrons containing apoB48 which are then released into the 
circulation (Havel & Kane, 1995). These lipoproteins distribute their TG load to the 
periphery via interaction with the lipoprotein lipase (LpL) anchored by heparan sulfate 
proteoglycans (HSPG) on the capillary endothelium. This enzyme catalyzes the hydrolysis 
of TG of the chylomicrons to free FA (FFA) which are then taken up by the peripheral 
tissues including adipose tissue and skeletal muscle. This process leads to a depletion of 
the chylomicron’s neutral lipid core, resulting in the formation of smaller particles called 
chylomicron remnants. These particles have lower TG content due to the lipolytic action, 
and are enriched in CE as compared to the original chylomicrons. During the 
transformation, these smaller particles acquire apoE and exchange other apolipoproteins 
with other lipoprotein classes. The half-life of both chylomicrons and remnants is very 
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short, reported to be less than 15 min in studies using radioactively-labelled retinyl 
palmitate (Berr & Kern, 1984; Cortner et al., 1987). Numerous studies indicate that the 
principal site of removal of these residues from the circulation is the liver (Attie et al., 
1982), and involves a series of complex processes in the space of Disse that include 
binding to HSPG, interacting with hepatic and lipoprotein lipases, and acquiring 
additional apoE (Mahley & Huang, 2007). The final step culminates in the delivery to the 
cell through receptor-mediated endocytosis, leading to internalization and degradation of 
the lipid particles in the lysosomal compartment of the hepatocyte. 
Very-low density lipoproteins (VLDL) are produced by the liver and transport 
endogenously-derived lipids (Havel & Kane, 1995). Similar to chylomicrons, these TG-rich 
lipid particles deliver lipids to the peripheral tissues through the LpL system, and acquire 
apoE and exchange other apolipoproteins with other lipoproteins. However, in humans, it 
is distinguished from intestinally-produced chylomicrons in that it contains apoB-100. 
Upon hydrolysis of TG by LpL, VLDL is converted to intermediate-density lipoproteins 
(IDL), and eventually to LDL. IDL is removed quickly from the circulation, and rarely 
detected in plasma. LDL which contains only one apoB100 per particle displays a half-life 
of 3-4 days, and represents the major carrier of CE in the circulation. LDL is ultimately 
removed from the circulation by the liver through receptor-mediated endocytosis through 



















Fig. 1. General diagram for TG-rich lipoprotein processing in the circulation. Lipoproteins 
carrying TG of exogenous (chylomicrons) or endogenous (hepatic-derived VLDL) origins 
circulate in the plasma to deliver their lipids to the peripheral tissues (adipose tissue, cardiac 
and skeletal muscle). The lipase system consisting of lipoprotein lipase (LpL) bound to the 
endothelial wall hydrolyzes the TG of these particles, and the lipolytic products (FFA) are 
delivered to the different tissues. The resulting particles reduced in TG content (chylomicron 
remnants, IDL, LDL) are then taken up for catabolism by the liver through receptor-
mediated endocytosis. Although LDL-R and LRP1 have both been implicated, evidence 
suggests the presence of other pathway(s) involved. 
www.intechopen.com
 Structure and Function of the Lipolysis Stimulated Lipoprotein Receptor 
 
269 
1.2.1 Receptor-mediated clearance of TG-rich lipoproteins 
1.2.1.1 LDL-R 
A major advance was made in the lipoprotein field by the discovery of the LDL-R by MS 
Brown and JL Goldstein (Brown & Goldstein, 1986; Goldstein & Brown, 2009). Their 
Nobel-prize winning research clearly showed the pivotal role of this receptor in body 
cholesterol homeostasis (Brown & Goldstein, 1997). The LDL-R that is defective in subjects 
with familial hypercholesterolemia (FH) (Goldstein et al., 1995) accounts for most of LDL 
removal. Although this receptor binds to both apoB100 and apoE, it does not seem to be 
the principal pathway for the removal of chylomicrons and their remnants. Indeed, 
clearance of chylomicron remnants proceeds at normal rates in humans and animals with 
genetic lesions impairing LDL-R function (Kita et al., 1982; Rubinsztein et al., 1990). 
Transgenic studies using LDL-R-/- mice nevertheless indicate that the LDL-R does 
participate, albeit partially to the clearance of chylomicron remnants (de Faria et al., 1996; 
Ishibashi et al., 1996).  
The identification of the receptor(s) involved with the LDL-R in the liver-specific capture of 
chylomicrons has remained a difficult task, and has been a subject of many lively debates. 
Initial efforts resulted in the identification of apoE-binding proteins not directly involved in 
receptor-mediated endocytosis of lipoproteins (Beisiegel et al., 1988). Other potential 
candidates proposed were later found not to be expressed in the liver such as the VLDL-
receptor and macrophage TG-rich lipoprotein receptor (Ramprasad et al., 1995; Sakai et al., 
1994). A candidate receptor that has received the greatest attention is the LDL-receptor 
related protein, LRP1, which belongs to the LDL-R family (Herz et al., 1988).  
1.2.1.2 LRP1 
LRP1 was originally discovered by cloning based on homologous recombination (Herz et 
al., 1988). Because of its shared domains to the LDL-R, its primary role was thought to be 
in the removal of lipoproteins from the circulation. Studies revealed that while this 
protein cannot bind LDL, it could recognize and bind ┚-VLDL isolated from cholesterol-
fed rabbits, but only when these lipid particles are enriched with added exogenous 
recombinant apoE (Kowal et al., 1989). It was later revealed that LRP was in fact the 
alpha2-macroglobulin receptor (Strickland et al., 1990), with multiple ligands including 
among others, activated macroglobulin, tissue-type (tPA) and urokinase (uPA) 
plasminogen activators, coagulation factors IXa, VIIIa, VIIa, TFPI, complement C3, and 
thrombospondin-1 (Herz & Strickland, 2001). LRP plays an important role in physiology 
since the absence of both alleles is embryonic lethal in mice (Herz et al., 1992). However, 
no remnant accumulation was observed in hepatic LRP1-inactive mice, and only a modest 
increase in apoB48-containing lipoproteins was observed when both hepatic LRP1 and 
LDL-R were inactive, suggesting that LRP plays a back-up role in the uptake of 
lipoproteins in the absence of the LDL-R (Rohlmann et al., 1998). Furthermore, LRP1 binds 
both apoE2/2 and apoE3/3 isoforms equally well (Beisiegel et al., 1989), which could not 
completely explain the mechanisms underlying type III hyperlipidemia which is often 
associated with the apoE2/2 phenotype (Soutar, 1989).  
Recent evidence has shown that LRP1 selective inactivation in adipose tissue increases LpL 
activity, but prevents uptake of TG in adipose tissue, thereby preventing weight gain and 
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insulin resistance (Hofmann et al., 2007). The authors propose that LRP1 mediates uptake of 
chylomicrons by adipocytes, and that this accounts for a large part of dietary TG clearance. 
However, it is difficult to imagine chylomicrons gaining direct access to adipocytes since 
unlike the liver with its space of Disse, the capillary endothelium is not fenestrated, 
therefore limiting access of these large bulky particles. The data nevertheless clearly show 
that LRP1 is necessary for proper processing of functional LpL. In absence of LRP1, the 
enzyme is present, but fails to deliver lipid to the underlying adipose tissue. If this is indeed 
the function of LRP1 in adipose tissue, this might also be the case for LRP1 in the liver. Thus, 
the modest hyperlipidemic effect in hepatic LRP and LDL-R inactive mice could be 
explained by mechanisms other than impaired receptor-mediated endocytosis, but rather by 
those involving LpL function. Other pathways as yet unidentified were clearly involved in 
the removal of TG-rich lipoproteins. 
This chapter focuses on the biochemical characterization, identification and function of the 
lipoprotein receptor which plays an important role in the removal of TG-rich lipoproteins 
during the postprandial phase. 
2. Biochemical characterization of LSR 
2.1 Original identification and characterization of an LDL-receptor independent 
pathway in LDL-receptor negative fibroblasts from a subject homozygous for familial 
hypercholesterolemia 
A study by Bihain et al revealed that FFA could regulate lipoprotein receptor activity, by 
showing that FFA inhibit binding of LDL to its receptor (Bihain et al., 1989). During these 
studies, it was discovered that in the presence of oleate, fibroblasts from a patient 
homozygous for familial hypercholesterolemia (FH fibroblasts) and therefore deficient in 
LDL-R were able to internalize a significant amount of LDL. A series of experiments were 
conducted to biochemically characterize this pathway apparently independent of the 
LDL-R (Bihain & Yen, 1992). The uptake of 125I-radiolabelled LDL increased in a dose-
dependent manner with the concentration of oleate used. The first question was to ask if 
cell viability was modified by the presence of FFA, which was not the case. Kinetic studies 
revealed that the internalization of LDL was time and dose-dependent, where saturation 
was achieved at 50 µg LDL protein/ml. Degradation products, measured as TCA-soluble 
125I released into the media appeared approximately 30 min after addition of oleate, which 
corresponds closely to the time required for delivery of ligands to the lysosome after 
internalization. Chloroquine, which is an inhibitor of lysosomal enzymes, prevented the 
appearance of 125I-products, confirming that the 125I-LDL internalized was delivered to the 
lysosome for degradation. It therefore appeared that the uptake of LDL into the cell 
through this LDL-receptor independent pathway was achieved through endocytosis, 
implying the presence of a receptor binding site of a specific nature on the cell surface 
plasma membrane (Bihain & Yen, 1992).  
Different FFAs were used to ascertain the nature of the potential binding site on the 
plasma membranes of the FH fibroblasts. It was found that the addition of a double bond 
rendered the FFA more efficient in activating this LDL-R independent pathway, as 
compared to the corresponding saturated analogs (Bihain & Yen, 1992). Interestingly, 
oleate, one of the more abundant FFA in plasma was found to be the most efficient 
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activator of this pathway. FFA analogs with uncharged residues such as oleyl alcohol or 
oleyl acetate also demonstrated a similar effect on LDL internalization, although slightly 
less efficient as compared to oleate (Bihain & Yen, 1992).  
Binding studies at 4°C revealed that in the presence of oleate, 125I-LDL bound with high 
affinity to a saturable and specific binding site on FH fibroblasts (Bihain & Yen, 1992). 
Bound LDL could be released by suramin, a polysulfated aromatic sodium salt, much in the 
same manner that heparin is used to release LDL bound to the LDL-R (Bihain & Yen, 1992). 
By comparing the amount of LDL bound to this oleate-induced binding site at 4°C to that 
released by suramin, it was determined that suramin released lipoprotein that was 
specifically bound to the cell surface. Treatment of cells with suramin during incubations 
with oleate and 125I-LDL simultaneously prevented the accumulation of cellular 125I-LDL as 
well as TCA soluble products, demonstrating that this binding site, once occupied by the 
ligand LDL, mediates internalization and subsequent degradation of the lipoprotein in the 
lysosome. Scatchard analysis of binding curves revealed characteristics of a single binding 
site with a Kd of 12.3 µg/ml and Bmax of 78.4 ng of LDL protein. 
Competition studies indicated that this binding site displayed a higher affinity for the TG-rich 
VLDL as compared to LDL (Bihain & Yen, 1992). This affinity for VLDL was directly related to 
the size of the particle and therefore TG content of the VLDL fraction, with the highest affinity 
being for the larger VLDL1 fraction, as compared to that for VLDL2 and VLDL3. Further 
studies revealed that chylomicrons or lipid emulsions containing recombinant apoE could 
compete with 125I-LDL for binding in the presence of FFA (Yen et al., 1994). Digestion of 
apoB100 on the LDL with mild pronase treatment renders the LDL unable to bind this oleate-
induced binding site, thus clearly demonstrating a direct protein-protein interaction between 
the lipoprotein ligand and the cell surface binding site. Derivatization of LDL with 
cyclohexanedione (CHD) modifies arginine residues of apoB resulting in a CHD-LDL unable 
to bind the LDL-R. Interestingly, CHD-LDL was able to compete for binding with 125I-LDL as 
well as normal unlabeled LDL. This modified LDL has been used to demonstrate the presence 
of a LDL-receptor independent pathway in human subjects (Simons et al., 1975), suggesting 
that perhaps this binding site may be involved in LDL-R-independent clearance. Finally, 
removal of cell surface proteins by mild trypsin treatment of the cell surface eliminated the 
cell’s capacity to exhibit oleate-induced binding, uptake and degradation of 125I-LDL (Bihain & 
Yen, 1992), clearly showing the protein nature of this cell binding site.  
Taken together, the initial characterization of this LDL-receptor independent pathway 
revealed that the FFA-induced binding, internalization and degradation of LDL was 
mediated by protein-protein interaction with a cell surface protein that recognized either 
apoB100 or apoE. Binding of the lipoprotein to this binding site in the presence of FFA leads 
to endocytosis, ultimately leading to lysosomal degradation of the lipoprotein particle.  
2.2 Identity of the lipolysis stimulated lipoprotein receptor, LSR distinct from LDL-R 
and LRP 
In view of the cell type used in these studies, it was clear that this binding site was not the 
LDL-R itself. Indeed, in FH fibroblasts, due to a significant deletion of the promoter region, 
these cells are unable to synthesize the LDL-R (Hobbs et al., 1987). Furthermore, it was 
previously demonstrated that FFA inhibit binding of LDL to the LDL-R. Other data that 
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characterize LDL binding outside of the cell using liver membrane assays described later 
will further confirm the distinct identity from the LDL-R of this FFA binding site. LDL was 
nevertheless used in these assays for technical reasons. First of all, LDL is easily isolated 
from human plasma in sufficient quantities for the type of studies that were performed. 
Secondly, LDL contains only one molecule of the large 500 kDa apoB100 that does not 
dissociate from the lipoprotein particle. Therefore, the 125I-radiolabel on the apoB100 of LDL 
provides an accurate measurement of the amount of lipoprotein particle itself bound, 
internalized and degraded by the cells. This is unlike the TG-rich lipoproteins, chylomicrons 
and VLDL, which contain a number of different apolipoproteins including apoE, as well as 
the apoA- and the apoC- classes of apolipoproteins. These apolipoproteins readily exchange 
between different lipoprotein particles, rendering it difficult to precisely measure the 
kinetics of the endocytosis. It was therefore deliberately chosen to continue using LDL as a 
ligand to study this pathway. 
At the time, the LRP1 had been cloned and then identified as being 100% homologous to the 
┙2-macroglobulin receptor. Questions arose as to whether this oleate-induced binding site 
could be LRP1. A number of evidence indicated that such was not the case. While it was 
necessary to supplement ┚-VLDL with exogenous recombinant apoE before binding by LRP, 
this was not necessary for ┚-VLDL binding in the presence of oleate in FH fibroblasts 
(Bihain & Yen, 1992). Experiments using activated ┙2-macroglobulin as a known LRP ligand 
demonstrated that there was no effect of oleate on LRP-mediated internalization and 
degradation of this ligand (Yen et al., 1994). Nor was the oleate-induced receptor inhibited 
by the 39 kDa receptor-associated protein (RAP) at concentrations shown to affect LRP 
activity (Yen et al., 1994). Furthermore, it had been shown that LRP was able to bind and 
recognize apoE2/2 (Beisiegel et al., 1989), while this oleate-induced pathway for lipoproteins 
was unable to bind to VLDL isolated from a type III hypertriglyceridemic patient with the 
apoE2/2 phenotype (Yen et al., 1994).  
Biochemical characterization of both receptors therefore revealed two distinct identities. It is 
interesting to note the two different approaches used to identify these two receptors. LRP 
was cloned based on its homology to specific domains of the LDL-R. The biochemical 
characterization of LRP revealed a multiligand receptor, for which lipoproteins were not 
necessarily the most important of ligands. Indeed, there are now numerous members of the 
LDL-R family that have been identified, all exhibiting diverse functions in physiology, at the 
level of both periphery and central nervous system (Herz & Strickland, 2001). While the 
protein and gene had been identified, it remained to determine the actual physiological role 
in lipoprotein metabolism of this receptor related to LDL-R. On the other hand, LSR was 
first identified and characterized functionally, as a receptor on the cell surface able to bind, 
internalize and degrade lipoproteins in the presence of FFA. It remained to identify the 
protein and gene responsible, in order to validate the physiological role of this receptor.  
By virtue of its activation by FFA, it was thought that this receptor would be active 
primarily during times when lipolysis is active, in other words during postprandial lipemia 
when there is increased levels of chylomicrons in the circulation. Indeed, lipases on the 
endothelial wall hydrolyze TG of chylomicrons and VLDL, two classes of lipoproteins that 
display the highest affinity for this LDL-receptor independent pathway. Because of this 
lipolysis-dependent step, the as yet unidentified receptor responsible for this pathway was 
named the lipolysis stimulated lipoprotein receptor, or LSR.  
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2.3 LSR in the hepatocyte 
2.3.1 Biochemical characterization of hepatic LSR 
The clearance of chylomicrons has previously been shown to take place in the liver through 
a receptor-mediated process (Sherrill & Dietschy, 1978). The LSR model had been 
biochemically characterized in FH fibroblasts, much in the same way as the LDL-R had been 
identified in normal human fibroblasts. Studies revealed that LSR activity was indeed found 
in primary cultured hepatocytes (Yen et al., 1994). However, although LDL cannot bind 
LDL-R in the presence of FFA, LDL-R activity in liver cells in the absence of oleate yielded 
interpretation of results difficult at times. Assays were developed using cell-free liver 
membranes in order to directly measure binding of lipoproteins to LSR. Binding studies 
using isolated liver total or plasma membranes revealed that LSR binding to 125I-LDL in the 
presence of oleate was Ca2+-independent (Mann et al., 1995). Indeed, LDL-R being a Ca2+-
dependent receptor (Goldstein et al., 1983), this provided additional evidence for the distinct 
identity between LSR and LDL-R. 
Further biochemical characterization using these assays revealed that the binding 
characteristics were similar to those observed for FH fibroblasts (Yen et al., 1994). 
Saturated FFA were less efficient in the activation of LSR as compared to oleate. Scatchard 
plots revealed again a single binding site with half maximum binding occurring at 23 µg 
LDL protein/ml. Heparan sulfate proteoglycans had been previously speculated to play a 
role in endocytosis of TG-rich lipoproteins (Eisenberg et al., 1992; Mulder et al., 1993; 
Williams et al., 1992). However, pretreatment of isolated liver membranes with 
heparinase/heparitinase and chondroitanase had no significant effect on oleate-induced 
binding of 125I-LDL to LSR, unlike trypsin, which diminished LSR activity in a time-
dependent manner leading to the disappearance of receptor binding after 60 minute 
treatment (Mann et al., 1995). Perfusion of livers with trypsin to degrade cell surface 
proteins before preparation of membranes also significantly diminished LSR binding 
activity by 80%, demonstrating that the majority of LSR activity measured occurs on the 
cell surface exposed on the extracellular side (Mann et al., 1995).  
2.3.2 Reversibility of LSR activation by FFA 
The development of these liver membrane assays allowed closer examination of the 
activation of LSR by FFA. Experiments revealed that the activation of LSR by FFA is 
reversible, but only if the binding site remains unoccupied (Mann et al., 1995). Albumin 
provided a means to remove FFA from the membranes after the activation step. Indeed, if 
membranes were washed with buffer containing albumin after incubation with oleate, 
binding of the lipoprotein to LSR did not occur. If after one series of activation by oleate 
and deactivation using albumin were performed, it was still possible to wash the 
membranes to remove the albumin, and then re-incubate the membranes in the presence 
of oleate with 125I- LDL. Binding of the lipoprotein to LSR was detected, indicating that 
FFA binding is reversible. However, if liver membranes are incubated with oleate, 
followed by the radiolabelled lipoprotein, the LSR-LDL binding complex remains stable. 
Washing with even very high concentrations of albumin after formation of the LDL-LSR 
complex is unable to dissociate the ligand from the receptor. These results suggested a 
reversible conformational change of LSR in the presence of FFA that reveals the apoB, 
apoE binding site. Once the ligand-receptor complex is formed, this appears to stabilize 
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the active LSR conformation. It is also possible that the FFA associated with the receptor 
or the surrounding phospholipid environment may be trapped within the complex, and 
inaccessible to the albumin in the washing buffer. These potential mechanisms remain to 
be tested in isolated systems using purified receptor.  
2.4 In vitro evidence for this receptor’s role in the hepatic clearance of triglyceride-
rich lipoproteins  
A number of circumstantial evidence for LSR’s potential role in hepatic clearance of 
lipoproteins was brought to light using these cell and membrane assays for LSR activity in 
the liver. Indeed, the measure of oleate-induced 125I-LDL binding under conditions in which 
maximal binding capacity of LSR is achieved represents an estimation of the apparent 
number of LSR on the hepatocyte membrane. Rats were sacrificed under non-fasted and 
fasted conditions, and plasma hepatocyte membranes isolated to measure maximal LSR 
binding activity. A strong negative correlation (r = -0.828, p < 0.001) was observed between 
the apparent number of LSR on the cell surface and the plasma TG levels measured at the 
time of the sacrifice of the animals (Mann et al., 1995). This implied that the higher LSR 
binding activity was, the lower the plasma TG levels. On the other hand, under fasting 
conditions, there was no significant correlation between these 2 parameters. Therefore, even 
in a normal sample population of laboratory rats, the variation in LSR corresponds to their 
ability to remove TG from the circulation, but only during the fed or postprandial state. This 
was the first in vitro circumstantial evidence pointing towards a potential role of LSR as a 
rate limiting factor for the removal of TG-rich lipoproteins during the postprandial phase.  
2.4.1 Lactoferrin  
Studies in the literature on the regulation of postprandial lipemia demonstrated that the 
milk protein, lactoferrin, when injected iv in rats led to increased TG during the 
postprandial phase by inhibiting clearance of chylomicrons (Huettinger et al., 1988). Indeed, 
lactoferrin contains a cluster of arginine residues, which is also found in the apoE binding 
site for the LDL-R. Further investigation showed that while lactoferrin delays chylomicron 
remnant clearance, it has no effect on ┙2-macroglobulin uptake in the liver, which is one of 
the principal ligands of LRP as discussed in an earlier section. Lactoferrin was found to 
inhibit LSR activity as a lipoprotein receptor in FH fibroblasts (Yen et al., 1994) and LSR 
binding activity in liver membranes (Mann et al., 1995). It was also observed that 
lactoferrin’s inhibitory effect was present only if LSR was in its FFA-activated form. Indeed, 
the presence of lactoferrin before addition of oleate had no effect on LSR’s ability to bind the 
lipoprotein ligand. Levels of membrane-associated oleate was not altered in the presence of 
lactoferrin, demonstrating that lactoferrin did not inhibit LSR activity by binding or 
removing FFA from the membranes (Mann et al., 1995). This supports the earlier data 
described above suggesting two distinct conformations of LSR, one conformation of the 
receptor in the absence of oleate, and a different conformation in the presence of oleate.  
2.4.2 ApoCIII  
ApoCIII is an apolipoprotein associated with TG-rich lipoproteins that plays a role in the 
modulation of plasma TG levels as a lipase inhibitor. Delayed clearance of TG-rich 
lipoproteins has been observed in mice overexpressing apoCIII (Aalto-Setala et al., 1992; Ito 
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et al., 1990). In addition, targeted disruption of apoCIII gene in mice leads to increased 
removal rates of chylomicron remnants associated with reduced TG levels during the 
postprandial phase (Maeda et al., 1994). Supplementation of VLDL with apoCIII led to 
decreased binding and uptake through the LSR pathway in primary cultures of rat 
hepatocytes (Mann et al., 1997). This was in contrast to apoCII, which displayed no such 
impact on VLDL binding to LSR. Furthermore, the degree of sialyation of apoCIII appeared 
to influence its ability to inhibit VLDL binding to this receptor (Mann et al., 1997). Therefore, 
the hypertriglyceridemic effect reported for apoCIII may be due in part to its inhibition of 
binding of VLDL to the LSR receptor, resulting in reduced hepatic capacity for the removal 
of TG-rich lipoproteins from the circulation.  
2.4.3 39 kDa receptor-associated protein  
Finally, the 39 kDa receptor-associated protein (RAP) is a protein that co-purifies with 
LRP1, and which was shown to inhibit binding of LRP ligands to their receptor (Herz et 
al., 1991; Moestrup & Gliemann, 1991; Williams et al., 1992). RAP overexpression using 
adenovirus vector in wild-type and LDL-R-/- mice led to an accumulation of plasma 
cholesterol and TG, as well as apoB-48 and apoE particles (Willnow et al., 1994). In this 
model, RAP levels were increased to a large extent in the animals. It was found that RAP, 
at concentrations similar to those used in this animal study inhibited oleate-induced 
binding, uptake and degradation of 125I-LDL through the LSR pathway (Troussard et al., 
1995). Lineweaver-Burk analysis revealed that this was due to a change in maximal 
binding capacity, rather than to a change in affinity (Troussard et al., 1995). Other studies 
also reported that at these levels, RAP could also affect LDL-R activity (Medh et al., 1995; 
Mokuno et al., 1994), therefore showing that the modifications in plasma lipids in RAP-
overexpressed mice were most likely to be due to inhibition of multiple lipoprotein 
receptors, rather than just LRP1 alone. 
The use of the different proteins that modulate TG and postprandial lipemia revealed a 
number of in vitro circumstantial evidence for the potential physiological role of LSR. 
Indeed, each protein shown to demonstrate a hypertriglyceridemic effect was determined to 
influence LSR activity as a lipoprotein receptor, whether directly on the receptor or 
indirectly through ligand binding to LSR. With this circumstantial evidence pointing 
towards a role of LSR in the removal of TG-rich lipoproteins during the postprandial phase, 
it remained to actually identify the protein or proteins responsible for LSR activity. 
3. Molecular characterization of LSR 
3.1 Purification of LSR 
Ligand blots were performed using human FH fibroblast lysates, in which cell lysate 
proteins were separated by SDS-polyacrylamide gel electrophoresis under non-reducing 
conditions, and then transferred to nitrocellulose (Yen et al., 1994). Interestingly, binding of 
125I-LDL in the presence of oleate was observed for 2 protein bands migrating at apparent 
molecular mass of 115 and 85 kDa. Mild trypsin treatment of cells before preparation of cell 
lysates demonstrated that these 2 proteins were located on the cell surface. These ligand 
blots were performed in the absence of Ca2+, which therefore eliminated the possibility that 
LDL was binding to the Ca2+-dependent LDL-R.  
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Upon identification of LSR activity in rat hepatocytes, liver membranes were prepared 
followed by treatment with n-octylglucoside (Mann et al., 1995), a mild non-ionic 
detergent often used to solubilize integral membrane proteins. An LSR-enriched fraction 
was prepared following further purification of the solubilized protein fraction by anion 
exchange chromatography, and was tested in ligand blots. These binding studies again 
revealed 2 bands at 115 and 90 kDa. A third band was also observed at around 230 kDa, 
which could represent either a homodimeric form of the 115 kDa band, or a heterodimeric 
form of the two lower molecular mass bands (Mann et al., 1995). The results of these 
ligand blots did reveal that this receptor, even when immobilized on nitrocellulose could 
be activated by oleate in absence of the phospholipid environment. This would therefore 
be consistent with the previous data suggesting a conformational change in the protein 
occurring following direct interaction of the FFA with the LSR proteins rather than with 
the surrounding membrane bilayer.  
The ligand blots allowed the study of LSR protein interaction with other proteins, 
including the 39kDa RAP (Troussard et al., 1995). Using a recombinant 39 kDa RAP fusion 
protein, it was found that this protein could bind directly to the same bands identified as 
displaying LSR binding activity. Interestingly, this binding did not require oleate. 
Furthermore, although preincubation with high concentrations of RAP fusion protein 
inhibited binding of the LDL ligand to oleate-activated LSR, LDL was unable to compete 
for RAP fusion binding to LDL. This suggested that the LSR binding site for RAP was 
distinct from that for the apoB component of LDL.  
3.2 Identification and cloning of the gene candidate 
Even after having identified LSR protein bands, it proved to be very difficult to isolate the 
LSR receptor. Indeed, ligand blots led to the speculation that this was indeed a complex 
composed of multiple subunits. It was discovered that the protein migrating around 240 
kDa rapidly degraded into multiple bands of different molecular masses once removed from 
the membrane phospholipid environment (Mann et al., 1995; Yen et al., 1999). Because of the 
lability of this complex, the purification of sufficient quantities in reduced form with 
adequate purity for microsequencing ended up being a major obstacle. Indeed, it was 
difficult to isolate the different bands from other contaminating proteins of similar 
molecular masses. Antibodies were prepared against the large 240 kDa complex by splicing 
out the band directly from the SDS gel and injecting into rabbits (Yen et al., 1999). These 
antibodies were validated in Western blots, identifying the same proteins also shown to 
bind radiolabelled LDL in the presence of oleate in corresponding ligand blots. This same 
antibody was also able to inhibit LSR binding activity in liver membranes, as well as LSR 
receptor activity in primary cultures of rat hepatocytes. Immunoprecipitation studies were 
performed with these antibodies using 35S-metabolically-labelled rat hepatocytes. Separation 
of the proteins under non-reduced conditions revealed 3 predominant bands at 240, 180 
kDa, and a third band migrating at 70 kDa previously unidentified in ligand blots, while the 
115 and 90 kDa proteins were also present, but only as weak bands (Yen et al., 1999). Under 
reduced conditions, all of these bands were detected, but only weakly, and 2 principal 
subunit bands with the molecular mass of 68 and 56 kDa were observed, with the 68 kDa 
band appearing sometimes as a doublet. The other bands originally identified in human FH 
fibroblasts and liver membranes were therefore most likely heterotrimer or tetramers of 
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these 2 subunits, hereafter referred to as ┙ (68 kDa) and ┚ (56 kDa), respectively. The lower 
molecular mass band of the doublet was referred to as ┙’. Mild trypsin treatment of the 
hepatocytes before preparation of the cell lysates provided evidence that these two subunits 
were located on the cell surface. Two-dimensional electrophoresis in which the 240 kDa 
complex was separated under non-reduced conditions, then isolated and then separated 
under reduced conditions revealed that these 2 bands were directly derived from the larger 
protein complex (Yen et al., 1999).  
This validated antibody was therefore used to screen a phage expression library of rat liver 
cDNA, from which a potential candidate gene was identified with an open reading frame 
within a Kozak consensus sequence (Yen et al., 1999).  
3.3 Bioinformatic analysis of the candidate gene 
Bioinformatic analysis of the predicted protein sequence of the candidate cDNA revealed a 
number of domains potentially indicative of a receptor (Bihain & Yen, 1998; Yen et al., 1999) 
(Figure 2).  
 
Fig. 2. Schematic diagram of the different domains of LSR. Analysis of the predicted sequence 
of the LSR protein shows that the longest form ┙ contains a hydrophobic region near the NH2 
terminal, a dileucine routing signal and a transmembrane domain. A cysteine-rich region is 
found as indicated, as well as a region rich in positively and negatively charged residues near 
the carboxylic end. The deletions for the forms ┙' and ┚ are also indicated (Bihain & Yen, 1998, 
reproduced with permission from Lippincott-Raven Publishers). 
A transmembrane domain was predicted based on the detection of an internal cluster of 
hydrophobic residues. Several motifs related to endocytosis were detected, including a 
phosphorylation site NPGY that potentially represents a clathrin-binding site (Chen et al., 
1990), as well as a dileucine lysosomal targeting signal (Dietrich et al., 1994; Shin et al., 
1991). Both of these domains were located on the N-terminal side with respect to the 
putative transmembrane domain, suggesting that the N-terminal was exposed 
intracellularly. On the N-terminal side of the protein, a smaller group of hydrophobic 
residues separated by a proline residue was located, which could be associated with the 
membrane phospholipids, providing a potential site of interaction with FFA. On the C-
terminal side of the transmembrane domain, a cysteine-rich region was found that is often 
observed in the family of cytokine receptor proteins (Bazan, 1990). On the C-terminal end 
of the protein was located a group of alternating negatively and positively charged amino 
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acids, which could represent the lipoprotein binding site. LSR is a phosphorylated 
receptor, with six phosphopeptides recently identified (Villen et al., 2007), for which the 
function remains to be determined. 
Northern blots revealed that mRNA of this candidate was detected in abundance in the 
liver, and in lesser levels in the kidney and lung, with none being detected in the muscle, 
spleen brain or heart (Yen et al., 1999). Multiple mRNAs detected in the liver led to a 
closer examination of the mRNA derived from this potential LSR gene. Indeed, RT-PCR 
using different primer sets with overlapping sequences revealed in actual fact 3 distinct 
mRNAs with base numbers corresponding to LSR 2097, 2040 and 1893. The predicted 
molecular mass for each corresponded to 65.8, 63.8 and 58.3 kDa, respectively, matching 
rather closely to the 3 bands, ┙, ┙’ and ┚, identified in the previously described immuno-
precipitation studies (Yen et al., 1999). The predicted sequence of ┙ corresponds to the full 
length protein containing all domains described. In ┙’, the sequence is practically identical 
with the exception of the loss of the dileucine repeat, suggesting that the intracellular 
routing of this subunit may differ from that of ┙. The ┚ subunit no longer contains the 
sequences for endocytosis and lysosomal targeting, the transmembrane domain and the 
cysteine-rich domain. This subunit however still contains both N-terminal hydrophobic 
domain for potential interaction with FFA or the cell membrane, as well as the C-terminal 
potential binding site for lipoproteins. Therefore, while the subunits ┙ and ┙’ are 
associated with the phospholipid bilayer, the ┚ subunit, although associated with the LSR 
complex, may be located either extracellularly or intracellularly. The role of each 3 subunit 
either as individual polypeptides or as complexes associated on the cell membrane surface 
remains to be clearly defined. 
The human lsr gene is located on chromosome 19 (19q13.12) (Bihain & Yen, 2005)(Genbank 
Gene ID: 51599). Interestingly, the LDL-R is located on chromosome 19 as well, but on 
19p13.2. Furthermore, the lsr gene is found upstream of a number of genes involved in lipid 
and lipoprotein metabolism including LIPE, which codes for the hormone sensitive lipase of 
adipose tissue involved in the insulin-controlled FFA release from adipose tissue. Further 
downstream is the apoE/apoCI,CII,CIV gene cluster, in which apoE is one of the potential 
ligands for LSR. The lsr gene structure contains 10 exons, from which are derived 3 mRNA 
products, 2 of which are alternatively-spliced products. Sequence analysis revealed that the 
mRNA LSR 2097 (┙) cited above represents the full-length sequence of all 10 exons, while 
the mRNA LSR 2040 (┙’) and 1893 (┚) represent alternatively spliced products in which 
either exon 4 (┙’) or exon 4 and 5 (┚) are deleted.  
4. Functional validation of LSR’s function 
4.1 In vitro studies 
Studies were conducted on CHO-K1 cells transiently transfected with the subunits ┙ and 
┚ (Yen et al., 1999). The transfection of each subunit individually led to increased binding 
and internalization of 125I-LDL in the presence of oleate. Only the co-transfection of both 
subunits completely restored LSR activity as a lipoprotein receptor leading to degradation 
of the lipoprotein particle. These results, along with the immunoprecipitation studies 
described earlier suggested that LSR present as a multimeric complex composed of at 
least ┙ and ┚ serves as a receptor for lipoproteins leading to delivery of the particle to 
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lysosomes for degradation via endocytosis. Each subunit appears to retain the capacity to 
bind the lipoprotein in the presence of oleate, consistent with the domains that are present 
in both polypeptides. However, the ┚ polypeptide does not contain the transmembrane 
domain, and it remains to be determined how it is expressed on the cell surface in the 
absence of the other LSR subunits. These functional in vitro data nevertheless supported 
the notion that the protein products derived from this candidate gene were responsible 
for LSR activity (Figure 3). 
 
Fig. 3. Hypothetical model of lipolysis stimulated receptor and its activation by FFA. (Top 
panel) Analysis of both biochemical data and that from Figure 2 allows us to propose that LSR 
could exist on the cell surface as a multimeric complex of one ┙ or ┙' (solid) subunit containing 
the transmembrane domain associated by disulfide bridges with two or three ┚ (gray) 
subunits, which would be exposed completely on the extracellular side. The predicted 
molecular masses would be 240 and 180 kDa. It is also possible that ┙ or ┙' subunits would be 
present alone on the plasma membrane surface. (Bottom panel) When FFAs are present, they 
bind to the hydrophobic regions, causing a conformational change of the LSR multimeric 
complex. This, in turn, exposes a binding site that, in this case, recognizes the apoE of a TG-
rich lipoprotein, leading to its binding, internalization and degradation. (Bihain & Yen, 1998, 
reproduced with permission from Lippincott-Raven Publishers) 
4.2 In vivo studies 
The next step was then to determine LSR physiological function in an animal model. The lsr 
gene was inactivated in 129/Ola ES cells by the deletion of a gene segment containing exons 
2-5, and then injected into mouse embryos. Complete suppression of this gene proved to be 
lethal at the embryonic stage (Mesli et al., 2004). Even though 3 LSR-/- males were produced 
in the initial reproduction, they proved to be weak and sterile. Mortality of the homozygote 
embryos occurred between days 12.5 and 15.3 of the gestation period. Interestingly, the 
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livers were abnormally small in these mice, suggesting that LSR was important for normal 
liver and embryonic development. Heterozygote LSR+/- mice proved however to be viable. 
Both immunoblots and quantitative PCR analyses demonstrated that hepatic LSR protein 
and mRNA were reduced by at least 50% in the LSR+/- mice (Yen et al., 2008b). 
Phenotypic analysis revealed that these LSR+/- mice with reduced expression of LSR 
displayed both increased postprandial lipemia and reduced clearance of TG-rich lipid 
particles (Yen et al., 2008b). These results are striking in that even in heterozygote mice 
expressing only one allele, the lower expression of LSR has a considerable impact on their 
ability to clear lipoproteins from the circulation during the postprandial state. Interestingly, 
if LDL-R was also absent in LSR+/- mice, postprandial lipemia was increased almost 2-fold as 
compared to LSR+/- mice with normal LDL-R activity, suggesting a cooperativity between 
these two receptors in the removal of apoB-containing lipoproteins.  
Both plasma cholesterol and TG levels increased in these mice when placed on a Western-
type diet containing high fat and cholesterol, primarily due to an increase in both TG-rich 
lipoproteins and LDL (Yen et al., 2008b). This was accompanied by increased lipid deposits 
in the aorta of the LSR+/- mice as compared to controls on the same diet, consistent with the 
atherogenic nature of these lipid particles. Interestingly, body weight gain of the LSR+/- but 
not LSR+/+ mice on the Western-type diet, was directly correlated with the increased plasma 
lipid levels (Yen et al., 2008b). This provided clear in vivo evidence for the physiological role 
of LSR in lipoprotein clearance during the postprandial phase, as well as a potential link 
provided by this receptor that could explain mixed hyperlipidemia (hypercholesterolemia 
and hypertriglyceridemia), weight gain and atherosclerosis. A recent study confirmed this 
in which adenovirus-mediated expression of siRNA specifically targeting hepatic LSR led to 
a significant increase in postprandial triglyceridemia, accompanied by increased levels of 
both apoB and apoE (Narvekar et al., 2009).  
Continued monitoring of LSR+/- mice on standard laboratory chow diet revealed 
significant weight gain and increased leptin with age as compared to control mice 
(Stenger et al., 2010). This was most marked in female LSR+/- mice, where body mass was 
increased 1.5 fold due to increased body fat mass, accompanied by a disproportionate 3-
fold increase in plasma leptin, a satiety hormone produced by the adipose tissue. 
Therefore, even under normal dietary conditions, a deficit in this receptor associated with 
elevated postprandial lipemia can lead to anomalies in both weight and plasma leptin. 
Indeed, hyperleptinemia is often observed in obesity, normally due to increased fat mass. 
It can be concluded therefore that by virtue of its role in the removal of apoB and apoE-
containing lipoproteins from the circulation, LSR also contributes to the regulation of lipid 
distribution between the liver and the peripheral tissues.  
4.3 LSR’s physiological role 
4.3.1 Clearance of TG-rich lipoproteins 
The in vivo data described above clearly point towards LSR playing an important role in 
the removal of TG-rich lipoproteins during the postprandial phase, a time in which there 
is considerable influx of chylomicrons containing dietary-derived lipids. As these particles 
enter the portal system, they are acted upon by the hepatic and lipoprotein lipases 
anchored to the endothelium by HSPG. The resulting hydrolysis of the TG core leads to 
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the release of FFA in the highly fenestrated space of Disse. This increased influx of FFA 
results in optimal activity of LSR, thus allowing the rapid removal of TG-rich particles 
and their remnants through this pathway. LSR therefore acts downstream of the lipolytic 
process as a hepatic receptor for the removal of TG-rich particles from the circulation 
(Figure 4). This conclusion is supported by a recent paper which reported that the 
removal of apoB-containing lipoproteins was inhibited in animals with reduced sulfation 
of heparan sulfate proteoglycans in the liver (MacArthur et al., 2007). Indeed, it was 
suggested that the removal of lipoproteins was mediated by a downstream pathway 
























Fig. 4. Diagram for LSR physiological function. During the postprandial phase, there is 
increased influx of chylomicrons (TG-rich lipoprotein) into the space of Disse, providing 
substrate for the lipase system (LpL and hepatic lipase, HL). This produces high levels of 
FFA, which activate LSR, leading to a conformational change exposing an apoB,E binding 
site for the TG rich particles and/or their remnants. A similar mechanism could occur for 
TG-rich VLDL. Evidence shows that different proteins (39 kDa RAP, lactoferrin or apoCIII) 
that can lead to increased plasma TG levels can also affect LSR activity. LSR can also bind 
apoB of LDL, and may serve as an LDL-receptor independent pathway, most particularly in 
conditions in which LDL-R is deficient or inactive. 
4.3.2 LDL-receptor independent pathway 
Although acting principally as a receptor for TG-rich lipoproteins, LSR can also bind and 
endocytose LDL. Its ability to recognize CHD-treated LDL clearly distinguishes this 
receptor from the LDL-R. If LSR participates in the removal of LDL, it can occur but only 
under certain conditions. Indeed, LDL is a cholesterol-rich particle and contains very low 
levels of TG, and thus is not a preferred substrate for lipases. It therefore would not be 
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able to generate sufficient lipolytic products to activate LSR, and its removal would occur 
primarily via the LDL-R. During the postprandial phase, the high influx of FFA in the 
space of Disse due to lipolytic activity on chylomicrons would inhibit binding of LDL to 
the LDL-R, while at the same time activating LSR. LDL could therefore be internalized by 
LSR during the postprandial phase, but only if concentrations are sufficiently high to be 
able to compete with the higher affinity TG-rich lipoproteins for binding to LSR (Figure 
4). Indeed, this hypothesis is supported by the increase in LDL and plasma cholesterol 
observed in LSR+/- mice on a high-fat cholesterol-containing diet (Yen et al., 2008b), as 
well as the increased plasma cholesterol following specific hepatic LSR knockout 
(Narvekar et al., 2009).  
This could provide an explanation for the large amounts of LDL that are cleared in FH 
subjects lacking the LDL receptor. Indeed, J Shepherd and colleagues postulated that this 
occurred via an LDL-R independent pathway based on their kinetic studies using CHD-
LDL (Simons et al., 1975). However, this liver-specific receptor-mediated process that was 
able to remove large quantities of LDL in both humans and animal models remained 
unidentified at the time.  
The LSR model therefore addresses two issues concerning 1) the removal of apoB,E-
containing TG-rich lipoproteins and 2) the clearance of LDL through an LDL-receptor 
independent pathway with the liver as the final destination.  
4.4 Regulation of LSR 
4.4.1 Leptin regulation of postprandial lipemia through its effect of LSR 
In the in vivo studies described above, LSR+/- mice demonstrated increased weight gain and 
a disproportionate increase in leptin levels with age, suggesting a potential connection 
between leptin and LSR. Leptin is an adipokine that plays a key role in the regulation of 
food intake and energy storage. Leptin exerts its anorectic effect at the level of the central 
nervous system by acting on hypothalamic neurons through its interaction with the long 
form of its receptor, ObRb. This binding leads to increased expression of ┙-melanocyte 
stimulating hormone (┙-MSH), a potent appetite inhibitor. However, leptin has also been 
described as a potent stimulator of synaptic transmission, by increasing N-methyl-D-
aspartate (NMDA) receptor at the cell surface (Moult et al., 2011; Oomura et al., 2006), 
neuroprotection and neurogenesis (Garza et al., 2008). Hence, leptin could represent much 
more than a simple on-off switch system controlling food intake and appetite behavior.  
The leptin receptor family is widely expressed in many tissue types, including the liver, and 
leptin itself has been shown to exert other peripheral effects including insulin production by 
the pancreas (Kahn et al., 2005; Morioka et al., 2007). The distention of the stomach following 
a meal can lead to increased leptin secretion by adipocytes, thus controlling appetite and 
energy storage, consistent with its effect as a satiety factor. It was recently demonstrated that 
leptin can regulate postprandial lipemia by increasing hepatic LSR protein levels (Stenger et 
al., 2010). Indeed, physiological concentrations of leptin (1 to 10 ng/mL) significantly and 
rapidly (within 1 h), increased LSR protein levels in vitro in Hepa1-6 cells. The leptin effect 
on LSR was confirmed in vivo in wild-type mice injected intra-peritoneally 8 days with leptin. 
Evidence indicated that leptin mediated this effect by promoting lsr gene transcription through 
the canonical MAPK/ERK pathway that is activated following leptin interaction with its 
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receptor. Interestingly, these leptin-treated mice displayed lower body mass, despite no 
significant change in food intake. Furthermore, endogenous liver TG output in the form of 
VLDL was higher, most likely to deliver energy substrate to the peripheral tissues. Thus, 
during the postprandial phase, leptin directly affects dietary lipid metabolism and storage 
through its action on LSR at the liver. This mechanism represents a lever for the regulation of 
dietary lipid uptake, degradation and distribution, thus contributing to maintaining an 
appropriate lipid homeostasis (Stenger et al., 2010) (Figure 5A).  
 
Fig. 5. Schematic diagram for leptin-mediated up-regulation of LSR and potential 
consequences on postprandial lipemia. A) We propose that the canonical leptin-induced 
signaling pathway involving phosphorylation of ERK leads to increased transcription of the 
lsr gene and increased protein levels of LSR at the surface of hepatocyte membranes. B) 
Under normal conditions, physiological levels of leptin are sufficient to maintain an optimal 
amount of LSR at the cell surface, permitting clearance of TG-rich lipoproteins during the 
postprandial phase. However, when leptin interaction with its receptor in the liver is 
impaired, such as in leptin resistance often observed in obesity, LSR protein levels at the cell 
surface may no longer be optimal, leading to decreased efficiency in removing lipids from 
the cell surface, resulting in elevated postprandial lipemia (Stenger et al, 2010, reproduced 
with permission from Faseb J). 
4.5 Other roles of LSR 
Other studies have recently appeared reporting other biological activities associated with 
LSR. LSR has been shown to be critical for the formation of tight tricellular contacts in 
epithelial cells, implying that this receptor is important for the maintenance of epithelial 
barrier function (Masuda et al., 2011). In view of the multimericity of LSR, it will prove 
interesting to determine the role of each of the LSR polypeptide subunits in the formation of 
these cellular junctions. A function has been identified for the full-length LSR ┙ subunit as 
host receptor for the binary toxin, Clostridium difficile transferase (CDT) (Papatheodorou et 
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al., 2011). By using a genome-wide haploid genetic screen on a derivative cell line of the 
human leukemia cell line KBM7, HAP1, the authors identified LSR as the potential host 
receptor, and then demonstrated increased reactivity to the toxin in cells expressing LSR. 
This would therefore point towards a specific role for one of the polypeptides of LSR. It 
remains however to determine if the other LSR subunits also demonstrate this activity.  
LSR expression was found to be inducible by p53 (Jazag et al., 2005; Kannan et al., 2001), and 
is specifically expressed in certain cancers, including bladder and colon (Herbsleb et al., 
2008), which would suggest a role during cancer development. siRNA studies used to 
inhibit LSR expression in bladder cancer cells led towards increased invasion capacity and 
cell motility of the cells, suggesting that p53-induced LSR expression may be aimed towards 
inhibiting the cancerous properties of cells. Additional studies remain to determine LSR's 
exact role in such circumstances. 
Finally, a homolog to LSR was identified by positional cloning with similar alternatively-
sliced mRNA products, that could potentially relate to the susceptibility of mice to type 2 
diabetes (Dokmanovic-Chouinard et al., 2008). Indeed, LSR does not demonstrate any 
distinct homology to other known receptors, which is why little is known about the 
relationship between its structure and function. The embryonic lethality of LSR when both 
alleles are absent does show that this gene and its protein product(s) are essential for 
development and viability of the embryo and newborn. While this may be due in part to its 
function as a lipoprotein receptor, it may also be related to the different functions identified 
here involving the integrity of tricellular junctions, as well as a role in the cell cycle.  
5. LSR as molecular link between hyperlipidemia, obesity and 
atherosclerosis 
Currently, all data on the physiological role of LSR are based on cell and animal models. The 
role of leptin in the regulation of LSR as well as the change in distribution of tissue lipids led 
towards the hypothesis that LSR could provide a molecular link between hyperlipidemia 
and obesity. Indeed, it was found that LSR expression was significantly diminished in obese 
mouse models, including the ob/ob, db/db and diet-induced obese (DIO) mouse (Narvekar et 
al., 2009; Yen et al., 2008a). If leptin either by its absence (ob/ob) or due to a leptin resistance 
(db/db or DIO) is unable to increase LSR levels during the postprandial phase, this could lead 
to suboptimal levels of this receptor. This in turn could explain the abnormalities found in 
plasma lipid profile often associated with obesity, most notably in the form of increased 
plasma TG and elevated postprandial lipemia (Figure 5B).  
The LSR+/- animal model demonstrates that even with 50% of LSR protein levels, this can 
lead eventually to increased weight gain and body fat mass. These changes are relatively 
small during early adulthood, but can develop with time into overweight issues leading to 
obesity, as was observed in aging LSR+/- female mice (Stenger et al., 2010). In addition, if 
dietary fat content is increased under conditions in which LSR is sub-optimal, this leads to 
accelerated accumulation of fat mass. Interestingly, LSR+/- mice on a 10-wk high fat diet 
exhibited both hyperleptinemia and impaired phosphorylation of the ERK kinase pathway, 
associated with a decrease in hepatic leptin receptor expression, as compared to age-
matched LSR+/+ littermates on the same diet. These results suggested that the low levels of 
LSR are directly associated with the appearance of a high-fat diet-induced peripheral leptin 
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resistance, for which the mechanisms remain to be elucidated. Peripheral leptin resistance 
combined with suboptimal levels of LSR during the critical moment of the postprandial 
phase leads to decreased efficiency in the removal of these atherogenic TG-rich lipoproteins 
from the circulation, as witnessed by the increased lipid deposits in the aorta of LSR+/- mice 
versus controls on a high fat and cholesterol-containing diet. (Yen et al., 2008). It remains to 
characterize the physiopathology of these lipid deposits and the molecular mechanisms 
involved. Nevertheless, together these data show significant modifications in lipid status 
directly related to LSR that may explain the link between hyperlipidemia and obesity, two 
significant risk factors for atherosclerosis. 
6. Conclusions and perspectives 
This chapter describes the biochemical characterization and identification of a receptor 
activated by FFA that plays an important role in lipid homeostasis as receptor for TG-rich 
lipoproteins during the postprandial phase. Its role in the removal of dietary lipids in the 
form of chylomicrons from the circulation directly impacts on lipid distribution in the 
peripheral tissues.  
It remains to be determined the importance of LSR in man. Numerous loci have been 
associated with obesity, body mass index and adiposity, including that located on 
chromosome 19q13, the loci on which the lsr gene is located. Indeed, linkage studies have 
identified this region as being associated with TG levels and obesity (Feitosa et al., 2006; 
Long et al., 2003). This locus has also been identified to contribute to serum lipid levels 
and dyslipidemia in genome wide association studies (Aulchenko et al., 2009; Kathiresan 
et al., 2009). It now remains to identify patients with deficiencies in LSR. It is unlikely that 
patients completely lacking LSR will be identified, since absence of this gene is lethal. 
Instead, it is possible that patients with genetic polymorphisms of the LSR gene leading to 
dysfunctional LSR may be discovered that are associated with hypertriglyceridemia or 
mixed hyperlipidemia. 
A majority of research has focused on elevated LDL cholesterol levels, which is an 
established risk factor for cardiovascular disease. The delineation of the role of LDL-R, as 
well as the discovery of the statins led to a better understanding in the control of cholesterol 
homeostasis (Goldstein & Brown, 2009). This, combined with an heightened public 
awareness of the increased risk of cardiovascular disease associated with high cholesterol, 
led to a steady decline in average plasma cholesterol levels in recent years. Nevertheless, 
cardiovascular disease remains top in the list of principal causes for mortality. Other 
therapeutic strategies have not proven to be conclusive (Couzin, 2008), demonstrating that 
other potential targets are needed for the development of other therapeutic strategies. 
Elevated postprandial lipemia is often observed in both obesity and patients with coronary 
heart disease. Indeed, TGs are an independent risk factor for cardiovascular disease 
(Goldberg et al., 2011; Lopez-Miranda et al., 2006). Such being the case, it is also important to 
find new ways to treat hypertriglyceridemia or mixed hyperlipidemia. 
The LSR model provides new insight in the molecular mechanisms involved in the 
development of hyperlipidemia and represents a molecular between hyperlipidemia, weight 
gain, and atherosclerosis. Further investigation is required to understand the underlying 
regulatory pathways involved. Nevertheless, it is clear that LSR is a new and promising 
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therapeutic target for the treatment of mixed hyperlipidemia. Optimal activation of LSR by 
preventive or therapeutic means can be envisaged to normalize clearance of lipoproteins 
during the postprandial lipemia, thereby preventing the accumulation of these high-risk 
lipid particles in the circulation. 
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